Polpharma’s services include EU standard dossiers for finished dosage formulations based on active pharmaceutical ingredients (API) developed in-house or outsourced. The company’s out-licensing (OL) portfolio secures the most comprehensive offer for its clients.
Co-operation with Polpharma can bring you several advantages, including:
- New products developed in three research and development (R&D) centers
- Very large portfolio to offer comprehensive dossiers
- Ten products in development and 20 products in early stage of development
- New products predominantly based on internally manufactured API
- Attractive products such as first generics, modern combo products and ophthalmic products without preservatives
- Dossiers meeting European guidelines adapted to local non-EU requirements
- Comprehensive manufacturing experience focused on lowering production cost
- Continuous out-licensing activity of our generic products with favourable conditions for our clients